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Abstract
Epidemiological studies have suggested an association between selenium intake and protection from a variety of cancer.
Considering this clinical importance of selenium, we aimed to identify the genes associated with resistance to selenium
treatment. We have applied a previous methodology developed by our group, which is based on the genetic and
pharmacological data publicly available for the NCI60 cancer cell line panel. In short, we have categorized the NCI60 cell
lines as selenium resistant and sensitive based on their growth inhibition (GI50) data. Then, we have utilized the Affymetrix
125K SNP chip data available and carried out a genome-wide case-control association study for the selenium sensitive and
resistant NCI60 cell lines. Our results showed statistically significant association of four SNPs in 5q33–34, 10q11.2, 10q22.3
and 14q13.1 with selenium resistance. These SNPs were located in introns of the genes encoding for a kinase-scaffolding
protein (AKAP6), a membrane protein (SGCD), a channel protein (KCNMA1), and a protein kinase (PRKG1). The knock-down
of KCNMA1 by siRNA showed increased sensitivity to selenium in both LNCaP and PC3 cell lines. Furthermore, SNP-SNP
interaction (epistasis) analysis indicated the interactions of the SNPs in AKAP6 with SGCD as well as SNPs in AKAP6 with
KCNMA1 with each other, assuming additive genetic model. These genes were also all involved in the Ca
2+ signaling, which
has a direct role in induction of apoptosis and induction of apoptosis in tumor cells is consistent with the chemopreventive
action of selenium. Once our findings are further validated, this knowledge can be translated into clinics where individuals
who can benefit from the chemopreventive characteristics of the selenium supplementation will be easily identified using a
simple DNA analysis.
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Introduction
Selenium is an essential dietary trace element with an
antioxidant function. It acts as a cofactor for the glutathione
peroxidase enzyme and is also incorporated into the selenoproteins
that are involved in antioxidant defenses [1,2]. Selenium is
incorporated in mammalian proteins as selenocysteine or seleno-
methionine, both of which are dietary forms of selenium, although
selenomethionine is the major form. Even though at high
concentrations it can be toxic to the biological systems, at low
concentrations selenium is implicated as a chemopreventive agent
in several cancers including breast, prostate, colon, lung and
ovarian cancers [1,2]. It has been particularly studied in relation to
prevention of prostate cancer where a direct link between the
serum levels of selenium and protection from the prostate cancer
was reported [3–5]. The chemopreventive action of selenium is
attributed to its ability to inhibit cell growth and to induce
apoptosis [1].
Given the obvious clinical importance of selenium in prevention
of cancer, it is important to understand the characteristics of
individuals’ response to selenium treatment. Variable response to
drugs (such as resistance and toxicity) is an existing issue and can
be partly attributed to the wide range of genetic variations among
individuals [6]. The likely genetic determinants of variable drug
response includes single nucleotide polymorphisms (SNPs), as well
as insertions, deletions, and inversions [7] that directly affect gene
expression and/or function. Among the genes identified so far in
variable drug response are the drug transporters, drug metabo-
lizers, drug receptors, apoptosis-regulating genes and chemokines
[6,8,9].
To date, identification of drug resistance and toxicity-associated
genes has been dependent on candidate gene approaches, which
requires prior biological knowledge. Here, we have applied a
genome wide association study (GWAS) using genetic (Affymetrix
125K) and pharmacological data from the NCI60 cell line panel
[10], with an aim to identify novel genes and genomic regions that
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12601are associated with selenium resistance. GWAS results indicated
the association of four genes with selenium resistance in the NCI60
cell line panel. RNA interference (RNAi) experiments showed that
the down regulation of one of these genes (KCNMA1) increased
sensitivity to selenium in both selenium sensitive (LNCaP) and
resistant (PC3) cell lines.
Results
Genetic Analyses
A total of 16 and 30 cell lines were categorized respectively as
sensitive and resistant to selenium in the NCI60 cell line panel
(Figure 1, Table 1). The single marker whole-genome case-
control association test results of 79,622 markers (with minor allele
frequencies (mAFs).2%) have demonstrated the most statistically
significant association with resistance to selenium, after conserva-
tive Bonferroni correction method (p=0.0009) and a less
conservative Benjamini and Hochberg method (FDR_BH
p=0.0009), for a SNP (rs2619641) located within the intronic
sequences of K
+ large conductance Ca
2+-activated channel,
subfamily M alpha member 1 (KCNMA1) at10q22. Application
of the Bonferroni and/or less conservative FDR_BH correction
method has implicated the significance of three other SNPs; SNP
rs32076 (p=0.02) of delta sarcoglycan (SGCD) at 5q33, SNP
rs10508958 (p=0.05) of type I (PRKG1, also known as PGK)a t
10q11, and the SNP rs8013938 (p=0.014) of cGMP-dependent
protein kinase A anchoring protein 6 (AKAP6) at 14q13 (Table 2).
Although, KCNMA1 represented the most likely candidate for
further analyses, we have discussed our findings in the context of
all four genes.
The SNP-SNP interaction (epistasis) has been also investigated
among the four candidate SNPs using a regression analysis and
correction by FDR_BH. As a result, we found statistically
significant interaction between the SNPs of AKAP6 and SGCD
(p=0.0125) and the SNPs of AKAP6 and KCNMA1 (p=0.0125)
assuming an additive genetic model. Information for the
populations screened and the minor allele frequencies of these
SNPs (rs32076 in SGCD, rs2619641 in KCNMA1, rs10508958 in
PRKG1, and rs8013938 in AKAP6) was available in the dbSNP
database [11]. These SNPs were found in the major historic
human populations (African, Asian and Caucasian) and were
detected in at least 4% of the chromosomes (not shown). In order to
evaluate the possible involvement of other nearby genes in the
observed resistance, we have checked the linkage disequilibrium
(LD) structures of these four genes. Our results suggested that the
four SNPs identified in this study were located within LD blocks
that were part of the KCNMA1, SGCD, AKAP6, and PRKG1 genes
and that did not extend beyond the gene boundaries. Therefore,
involvement of other nearby genes in the observed resistance is not
likely. An extensive literature search for these 4 SNPs did not
reveal any known functional consequences (such as on gene
expression or protein function). Thus, the direct biological
relationships between these SNPs and resistance to selenium
treatment observed in NCI60 cell lines panel remain unknown.
However, based on the statistical associations detected, we can
hypothesize that the functions of the genes that these SNPs are
located in are required for resistance to selenium. Therefore, down
regulation of expression of these genes may reverse the resistance
to selenium and induce sensitivity to selenium treatment in cells
(i.e. cell death would be observed). Thus, to test this hypothesis, we
performed RNA interference (RNAi) experiments.
Functional Analyses
We have previously reported that LNCaP cell line is relatively
much more responsive to selenium treatment when compared to
androgen receptor (AR) deficient PC3 cell line [12]. We utilized
Figure 1. Distribution of NCI60 cell lines with respect to their response to Selenium treatment.
doi:10.1371/journal.pone.0012601.g001
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reduced expression levels of KCNMA1 (the most significant
candidate) in PC3 as well as in LNCaP cell lines. Both cell types
were transfected by RNAi probes, and the cell proliferation MTS
assays were performed in triplicates. The results were adjusted for
the difference between cells with scrambled RNAi, untreated and
those treated with selenium. As expected, the treatment of
scrambled control cells treated with selenium resulted in 29%
reduction in growth of LNCaP cells, whereas there was only a
7.7% reduction in growth observed in PC3 cell line. The siRNA
knockdown of KCNMA1 has shown increased sensitivity to
selenium treatment with all the probes where statistical signifi-
cance was obtained with K7 in LNCaP (p=0.047) and K6 in PC3
(43.8% difference, p=0.049) cell lines (Figure 2).
To evaluate the portion of the mRNA expression knocked down
we have carried out a real-time PCR assay of PC3 cells transfected
and untransfected with KCNMA1 probes 6 and 7, before and after
selenium treatment. The treatment with selenium caused a
reduction in the expression of KCNMA1 in PC3 cell lines in
comparison to scram cells (untreated with siRNA) (Table 3). A
further 2-fold reduction in K6 and K7 expression is also observed
when compared to the corresponding cells untreated with
selenium.
Discussion
Selenium is an essential trace element and a potent regulator of
eukaryotic cell growth. Within the cell, it is incorporated as
selenocystein into a small group of 25 selenoproteins that are
involved in redox regulation of intracellular signaling and
antioxidant function [2,13]. The selenium-containing enzymes
glutathione peroxidases are known to be induced by oxidative
stress as well [14]. In addition, genetic polymorphisms of
selenoproteins have been shown to affect carcinogenesis indirectly
by influencing selenium metabolism [15].
Recent epidemiological and animal model studies have
demonstrated that selenium may be an effective chemopreventive
agent against several human cancers, including colorectal and
prostate cancers [3,16–19]. Specially, in the last decade, selenium
alone or in combination with other agents have been speculated as
an effective chemopreventive agent against prostate cancer, in
spite of some controversy [19–21]. For example, a recent report on
the SELECT trial implicates that Selenium and/or vitamin E did
not prevent prostate cancer [21]. However, it is likely that
selenium may be a chemopreventive agent in other cancers.
Selenium is thought to exert its anticarcinogenic effect through a
variety of mechanisms leading to apoptosis triggered by Ca
2+
signaling, intrinsic mitochondrial pathway, formation of reactive
oxygen species, and activation of caspases [2,15,22–24].
The activity of selenium is strictly dependent on its serum and tissue
concentrations; while the lower concentrations induce cell growth, the
higher concentrations inhibit growth and induce cell death [25–27].
Uguz et al. have also investigated the effects of different selenium
concentrations in HL-60 cells, where they have demonstrated that at
low concentrations (200 nM) selenium induces a mild endoplasmic
reticulum (ER) stress whereas this stress is much more severe at higher
concentrations (1 mM) [26]. These studies have demonstrated the
dose dependent effects of selenium in mediating cell growth and death
via modulating the Ca
2+ release from the ER [25,26]. Calcium
signaling has been shown to be regulated by the selenoproteins upon
selenium supplementation in human endothelial cells [28]. In some
studies, selenomethionine was shown to inhibit colon tumor [29] and
prostate tumor [30] cell growth at the G2/M checkpoint, which was
followed by apoptosis. Therefore, these findings indicate a chemo-
preventive effect of different concentrations of selenium on oxidative
stress-induced apoptosis.
In this study, to investigate genetic variations affecting the
response to selenium, we utilized an innovative statistics-based
method previously reported by us [31]. Our model integrates the
analysis of the genome wide genetic data with the response data
obtained from the selenium treated NCI60 cell line panel. Our
results demonstrated a statistically significant association of the
selenium resistance with four SNPs in the intronic regions of four
genes; (a) KCNMA1 (also known as BK-and Maxi K+ channel), a
large conductance, voltage and Ca
2+-sensitive K+ channel located
on the plasma membrane. KCNMA1 activation has a great impact
on the membrane and plays role in muscle tone/contractility and
neuronal activity [32] as well as blood pressure regulation [33]; (b)
PRKG1, a serine-threonine kinase located in the cytoplasm with a
key role in nitric oxide/cyclic guanosine monophosphate (cGMP)
signaling. PRKG1 functions directly as a redox sensor directly
activated by oxidation in vitro, and in rat cells and tissues [34].
This oxidation-induced activation represents an alternate mech-
anism for regulation along with the classic activation involving
nitric oxide and cGMP; (c) AKAP6, a member of the cAMP
Table 1. NCI60 cell line panel selenium response phenotypes.
Selenium Resistant Cell Lines Selenium Sensitive Cell Lines
1 786O A549ATCC
2 A498 CAKI1
3 ACHN CCRFCEM
4 COLO205 HCT116
5 HOP62 HL60
6 HT29 HOP92
7 K562 IGROV1
8 KM12 NCIH226
9 LOXIMVI NCIH23
10 M14 NCIH460
11 MALME3M OVCAR4
12 MOLT4 SF295
13 NCIH322M SF539
14 NCIH522 SNB75
15 OVCAR3 U251
16 OVCAR5 UO31
17 OVCAR8
18 RPMI8226
19 SF268
20 SKMEL2
21 SKMEL28
22 SKMEL5
23 SKOV3
24 SN12C
25 SNB19
26 SR
27 SW620
28 TK10
29 UACC257
30 UACC62
doi:10.1371/journal.pone.0012601.t001
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located on the endoplasmic reticulum/sarcoplasmic reticulum
(ER/SR). AKAP6 is selectively expressed in brain, cardiac and
skeletal muscle [36] and it is specifically localized in the SR,
therefore, sequestering PKA to this organelle [36]; and (d) SGCD,
a member of Sarcoglycan family critical in linking cytoskeleton to
extracellular matrix. SGCD directly stabilizes the link between
dystroglycan and dystrophin/utrophin.
Interestingly all four candidates identified were previously shown
to be involved in Ca
2+ signaling and the regulation of intracellular
Ca
2+ concentrations during cell growth and death. Intracellular
Ca
2+ concentration, a key cellular mechanism regulating cell
proliferation and death, is mainly mediated by the plasma
membrane associated voltage-gated ion channels as well as the
RYR and ITPR channels on the ER. KCNMA1 directly interacts
with the alpha subunit of CACNA1C channel [37] leading to Ca2+
influx, opening of KCNMA1 channel, and efflux of the intracellular
K+. Italsoisakeymoleculeindepolarizingthemembranepotential
to the resting stage [38]. Interestingly, our second candidate,
PRKG1, a serine-threonine kinase, also activates opening of the
KCNMA1 channel via phosphorylation [39,40]. PRKG1 has been
shown to lower intracellular concentration of Ca
2+ in platelets
(inhibiting platelet activation), smooth muscle cells (inhibiting
contraction), endothelial cells (inhibiting permeability), and cardiac
myocytes (depressing contractibility) [41–43]. AKAP6, located on
the ER/SR, acts as an adapter molecule in co-localization of the
PKA, which also phosphorylates and regulates the activity of
KCNMA1 [44,45]. In human dermal fibroblast, PKA is involved in
activation of the KCNMA1 by nitric oxide through cGMP [44]. In
addition, a recent study reviews the role of AKAP6 in integration of
cAMP (i.e. PKA signaling) and Ca
2+ signaling [46]. The last
candidate, SGCD is an essential member of the sarcoglycan
complex which was also implicated in regulating intracellular Ca
2+
concentration [47]. In fact, its deficiency was implicated in
abnormalCa
2+regulation [48],whileitsmutations lead toincreased
Ca
2+ permeability and apoptosis in vascular smooth muscle cells of
Syrian hamster [49]. Therefore, the functional characteristics of the
genes identified in this study are related to each other (Figure 3).
These four genes identified in this study also were implicated in
human diseases, such as cancer. For example, alteration of
KCNMA1 function has been associated with several complex
human disorders including cancer. KCNMA1 expression was found
to be higher in breast tumors and brain metastases [50]. KCNMA1
was also found amplified in 16% of the human prostate cancer
[51]. Alterations of PRKG1 have been implicated in the origin of
clonal expansion of primary tumors from breast cancers [52],
hepatocellular carcinomas [53] and uterine leiomyomas [54]. Also,
according to the COSMIC website, PRKG1 and AKAP6 were
somatically mutated in some cancers (http://www.sanger.ac.uk/
genetics/CGP/cosmic/). SGCD complex, which is involved in
proper muscular functioning, has been associated with the limb-
girdle muscular dystrophy and cardiomyopathy [47,55].
Using the RNAi technology, we have investigated the response
of PC3 and LNCaP cell lines to selenium treatment in the presence
of low expression levels of KCNMA1, the most significant candidate
gene discovered in the present study. The knock-down of
KCNMA1 by K6 and K7 siRNA probes displayed similar trend
of increased sensitivity to selenium treatment of PC3 cell lines. The
statistical significance was obtained for K7 probe in relatively
sensitive LNCAP cells, whereas the K6 probe was found
significant in the relatively more resistant PC3 cell line. The
knockdown ratio of KCNMA1 mRNA expression has validated the
reduced expression in cells treated and untreated with selenium.
Evaluation of the mRNA expression of KCNMA1 by qRT-PCR in
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12601the significant probe sets (K6 and K7) showed 2-fold decrease in
gene expression in the selenium-treated cells. KCNMA1 is shown to
be amplified in primary prostate cancer tumors and PC3 cell line,
and siRNA knock-down implicates KCNMA1’s critical role in
prostate cancer development [51]. The observed variability in
response to different probes of KCNMA1 might be explained by
target specificity, and the functional interplay between these and
other genes in the cell lines studied.
Finally, given the strong functional relationship among the
candidate genes, using statistical methods, we have also investi-
gated the gene-gene interaction (epistasis), demonstrating possible
interactions, between the SNPs of KCNMA1 and AKAP6 as well as
AKAP6 and SGCD, under the additive model. Further studies are
warranted to fully investigate the individual and interactive roles of
these genes in selenium resistance.
In summary, we have performed a whole-genome case-control
study using the already existing NCI60 cell line panel data to
identify candidate genes involved in resistance to selenium
treatment. Our results identified four genes all of which are
involved in calcium signaling, which is in agreement with other
studies stating that at least a part of the chemopreventive
characteristics of selenium is through its ability to kill tumor cells
by inducing apoptosis or by its antioxidant capabilities. However,
we also highlight the fact that the combination of genes rather
than a single-gene effect may lead to the lack of stronger response
in cells, therefore further studies are warranted. Identification of
the true genetic basis of the resistant/sensitive phenotypes by
further studies will help understanding the molecular basis of
selenium resistance. Once confirmed, these findings will find a
direct application in clinics where individuals who can benefit
Figure 2. KCNMA1 knock down in LNCaP and PC3 cell lines using siRNA methodology. The percent reduction in response is plotted as a
bar graft, the first bar in each set indicating the absence and the second bar representing the presence of selenium treatment of both cell lines. The
siRNA experiments are done in triplicates and the average is taken. The (*) indicates the statistically significant (p,0.05) differences in response to
selenium treatment.
doi:10.1371/journal.pone.0012601.g002
Table 3. qRT-PCR results for KCNMA1 knock down.
Beta actin KCNMA1 Ratio KCNMA1/Beta actin
CT Gene Copy # Average CT Gene Copy # Average
C 15.2 2255.1 2176.0 17.5 2691.8 2937.3 1.4
C 15.3 2096.8 17.3 3182.7
C+SE 14.1 4546.9 4531.9 16.9 4154.5 4076.9 0.9
C+SE 14.1 4516.9 17.0 3999.3
Sc 14.4 3607.1 3756.1 17.0 3909.0 4000.3 1.1
Sc 14.3 3905.1 17.0 4091.7
Sc+SE 13.8 5508.5 5490.4 16.9 4154.5 4477.8 0.8
Sc+SE 13.8 5472.2 16.8 4801.0
K6 14.6 3331.8 3245.9 18.5 1316.0 1301.1 0.4
K6 14.6 3160.1 18.5 1286.3
K6+SE 14.6 3266.3 3277.2 19.4 648.3 673.9 0.2
K6+SE 14.6 3288.0 19.3 699.6
K7 14.5 3443.9 3450.1 18.0 1811.8 1811.8 0.5
K7 14.6 3456.2 18.1 1819.9
K7+SE 14.1 4607.5 5265.9 18.3 1486.5 1144.4 0.2
K7+SE 13.7 5924.3 19.1 802.3
C: control, Sc: scram, SE: selenium.
doi:10.1371/journal.pone.0012601.t003
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and straightforward DNA test.
Materials and Methods
Categorization of Selenium Resistant and Sensitive NCI60
Cell Lines
We have followed a methodology previously described by our
group [31], which is based on the publicly available biological and
pharmacological data on the NCI60 cell lines [10]. In short, the
GI50 data (the amount of the tested compound, in this case
selenium methionine, required to inhibit growth of 50% of the
cells) were obtained from the Developmental Therapeutics
Program (DTP) website (http://dtp.nci.nih.gov/index.html). To
determine selenium resistant and sensitive NCI60 cell lines, the
log10 of GI50 values at concentration of 10
24 M were normalized
to obtain a mean of zero and standard deviation of one. Then SAS
9.1 (PROC UNIVARIATE) was applied to estimate the density
function of the normalized GI50 values using a normal kernel
estimation procedure with an optimal bandwidth estimated at
0.2467 and an asymptotic mean integrated squared error (AMISE)
of 0.0206. The density function showed three modes: the NCI60
cell lines with values higher than 0.1 were assigned to the resistant
group whereas the cells with values below 0.1 were assigned to the
sensitive group (Figure 1). A total of 16 and 30 cell lines were
defined as sensitive and resistant, respectively (Table 1).
Whole-genome Case-Control Association Study
The Affymetrix 125K SNPs data for the NCI60 cell line panel
[56] was downloaded from the DTP website (http://dtp.nci.nih.
gov/mtargets/download.html) and was utilized in a whole-
genome single SNP case-control association analysis performed
by the PLINK software [57] using the standard chi-square test on
allelic frequencies. The information related to the populations
genotyped for the three SNPs with rs numbers and their minor
allele frequencies were retrieved from the dbSNP database build
128 [11]. The PLINK parameters were set to include SNPs that
have been genotyped in at least 75% of the cells and had a
minimum minor allele frequency (mAF) of 2%. A total of 79,622
markers satisfied these criteria and were used for the association
testing. Correction for the multiple testing to decrease the false-
positive associations was performed by PLINK using methods such
as the False Discovery Rate by Benjamini and Hochberg
(FDR_BH) [58]. Results with p values ,0.05 were considered
significant. The information related to the populations genotyped
for the four SNPs and their minor allele frequencies were retrieved
from the dbSNP database build 128 [11].
Linkage Disequilibrium Structures
The genotype data for the European samples (CEU) for the
KCNMA1, SGCD, AKAP6, and PRKG1 genes were retrieved from
the International HapMap Consortium database [59]) and
analyzed using the Haploview program [60].
SNP-SNP Interaction Analysis
We used the logistic regression model to analyze two-way
interactions among the SNPs that were found individually
associated with selenium resistance. This analysis was done using
an additive model for each SNP. To test the significance of SNP-
SNP interaction, we fit and compare two models, one with the
SNP main effects only and the other with the main effects and two-
way interaction effect, and calculate the likelihood ratio test and its
associated p-value based on ANOVA. The results were corrected
for multiple testing using the FDR_BH [58]. This correction
Figure 3. A schematic representation of relationships among the KCNMA1, SGCD, PRKG1, and AKAP6 proteins.
doi:10.1371/journal.pone.0012601.g003
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siRNA Transfection of Prostate Cancer Cells
Two established human prostate cancer cell lines, LNCaP
(androgen responsive) and PC3 (androgen independent) were
obtained from the American Type Culture Collection (Rockville,
MD). LNCaP cells was cultured in RPMI 1640 with L-glutamine
(Life Technologies, Inc., Grand Island, NY), supplemented with
10% FBS, and 100 IU/ml penicillin and 100 mg/ml streptomycin.
PC3 cells were cultured in DMEM/F12 medium with 10% FBS
and antibiotics. All of the cell types were maintained at 37uCi na
humidified atmosphere of 5% CO2 in air. LNCaP and PC3 cells
cultured in medium were either transfected with siRNA
(QT00065660 SGCD primers; QT00024157 KCNMA1 primers)
or remained untransfected, and treated with selenium or untreated
in triplicates. A total of 12.5 ng siRNA in 1–3 ml of siRNA in
suspension Buffer/RNase-free water was spotted into a single well
of a 96-well plate. Diluted HiPerFect Transfection Reagent was
added to the pre-spotted siRNA (0.75 ml of HiPerFect Transfec-
tion Reagent to 24.25 ml of culture medium without serum) and
incubated for 5–10 min at room temperature (15–25uC) to allow
formation of transfection complexes. Following these 5000 cells in
175 ml of an appropriate culture medium (containing serum and
antibiotics) was seeded into the well, on top of the siRNA–
HiPerFect Reagent transfection complexes. Cells were incubated
with the transfection complexes under their normal growth
conditions for 6–24 hours. Cells were treated with selenium
(150 mM) or vehicle alone and proliferation was monitored after
72 h by the MTS assay as described previously [12]. All
experiments were carried out in triplicates at the same time and
under similar culture conditions. The difference between the cells
transfected with scram versus siRNA probes was tested by paired t
test after adjustment for the response difference of scram.
Real Time Quantitative PCR (qRT-PCR)
PC3 cells cultured in medium were either transfected with
siRNA or untransfected, and treated with selenium or untreated.
After 72 hrs of incubation, about 3610
6 cells were harvested from
respective plates and used for RNA extraction. RNA extraction
was done using RNeasy mini kit (Qiagen Inc, Canada) according
to the manufacturer’s protocol. Contaminating chromosomal
DNA was digested with RNAse free DNAse (RNAse free DNAse
kit, Qiagen inc, Canada) following the optional step during the
RNA extraction protocol. Further RNA was analyzed both
qualitatively and quantitatively by measuring OD 260/280.
A one step real time PCR using the KCNMA1 primers (Qiagen)
was performed in special 96-well TaqMan optical reaction plate
format on a ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster city, CA, USA). Beta-actin was used as the
endogenous control gene. Each 50 ml reaction contained Qiagen
SYBR green master mix, gene specific forward and reverse primer
and probes for target and control gene (Qiagen Inc, Canada). To
obtain PCR conditions with reduced variability, premixes
containing primers and probes and PCR master mix except
template RNA were aliquoted into 96-well optical reaction plates.
Standard, unknown samples and no template control (NTC) were
added in a volume of 5 ml. Serial dilutions of standard ranging
from 1:5 dilutions (5 fold dilutions) were set up for beta actin
control and KCNMA1 target in separate duplicate wells. Thermal
cycling parameters included, reverse transcription 30 min 50uC,
PCR activation step 15 min 95uC, followed by 40 cycles of 15
seconds at 94uC, 30 s at 55uC and 30s at 72uC. The number of
target gene copies was extrapolated from a standard curve
equation generated with serial dilutions of a known amount of
standard RNA. The normalization of samples was performed by
dividing the number of copies of KCNMA1 gene by the number of
copies of beta actin. All further PCR for KCNMA1 mRNA
quantification were performed using standard RNA dilution
curves. The intra assay variability was ,3%.
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